Abstract
Background:
The aim of this study is to evaluate distribution and clinical impact of the SS18-SSX fusion gene in patients with synovial sarcoma in China.
Methods:
We collected and analysed the clinical data of 88 patients using univariate and multivariate survival analysis. HEK 293T and NIH 3T3 cell lines were transfected with the SS18-SSX1 or SS18-SSX2 gene to determine the respective involvement of these fusion genes in cell proliferation and invasion.
Results:
Overall survival was significantly better among SS18-SSX2 cases (P=0.001), FNCLCC grade 2 cases (P<0.001), and UICC stage 1 or 2 (P<0.001) by univariate and multivariate survival analysis. SS18-SSX1-positive cells were more proliferative and invasive than SS18-SSX2-positive cells.
Conclusion:
SS18-SSX fusion type is a significant prognostic factor for patients with synovial sarcoma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Animals
-
Biomarkers, Tumor / genetics
-
Cell Growth Processes / genetics
-
Child
-
Female
-
HEK293 Cells
-
Humans
-
Male
-
Mice
-
Middle Aged
-
NIH 3T3 Cells
-
Neoplasm Invasiveness
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
Oncogene Proteins, Fusion / genetics*
-
Oncogene Proteins, Fusion / metabolism
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins / metabolism
-
Repressor Proteins / genetics*
-
Repressor Proteins / metabolism
-
Retrospective Studies
-
Sarcoma, Synovial / genetics*
-
Sarcoma, Synovial / metabolism
-
Sarcoma, Synovial / pathology
-
Survival Analysis
-
Transfection
-
Young Adult
Substances
-
Biomarkers, Tumor
-
Neoplasm Proteins
-
Oncogene Proteins, Fusion
-
Proto-Oncogene Proteins
-
Repressor Proteins
-
SS18 protein, human
-
SYT-SSX fusion protein
-
synovial sarcoma X breakpoint proteins